Aktis Oncology Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aktis Oncology (AKTS).

Price Target Range — 5 Quarters

Analyst Consensus — 9 Analysts

1S.Buy

7Buy

1Hold

Consensus RatingOutperform# Analysts9Avg. Consensus PT$32Upside to Avg. PT+104.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 2, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$35
Sep 9, 2026	Oppenheimer	Jeff Jones	Initiate	Outperform	$40
Aug 19, 2026	Wedbush	David Nierengarten	Initiate	Outperform	$35
Aug 19, 2026	BMO Capital	David Lebowitz	Initiate	Outperform	$37
Jul 14, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$30→$33
Jun 16, 2026	Raymond James	Christopher Raymond	Initiate	Strong Buy	$40
Jun 2, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$33→$35
Apr 29, 2026	William Blair	Alexandra Ramsey	Initiate	Outperform	—
Mar 31, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$30→$33
Mar 9, 2026	HC Wainwright & Co.	Robert Burns	Initiate	Buy	$30
Feb 3, 2026	Leerink Partners	—	Initiate	Outperform	$31
Feb 3, 2026	JP Morgan	Jessica Fye	Initiate	Overweight	$30
Jan 4, 2024	Piper Sandler	Harsh Kumar	Downgrade	Overweight→Neutral	$2→$1

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target

Wedbush analyst David Nierengarten reiterates Aktis Oncology (NASDAQ:AKTS) with a Outperform and maintains $35 price target.

Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40

Oppenheimer analyst Jeff Jones initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $40.

Benzinga Newsdesk

PRO
Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35

Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $35.

Benzinga Newsdesk

PRO
BMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37

BMO Capital analyst David Lebowitz initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $37.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Aktis Oncology, Raises Price Target to $33

JP Morgan analyst Jessica Fye maintains Aktis Oncology (NASDAQ:AKTS) with a Overweight and raises the price target from $30 to $33.

Benzinga Newsdesk

This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Top Wall Street analysts changed outlook on top names. For all changes, including upgrades/downgrades, visit analyst ratings page. Consider buying AKTS stock? Analysts weigh in.

Avi Kapoor

Aktis Oncology Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Aktis Oncology Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target

PRO
Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40

PRO
Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35

PRO
BMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37

PRO
JP Morgan Maintains Overweight on Aktis Oncology, Raises Price Target to $33

This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

People Also Watch

People Also Watch

Aktis Oncology Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Aktis Oncology Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target

PROOppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40

PROWedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35

PROBMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37

PROJP Morgan Maintains Overweight on Aktis Oncology, Raises Price Target to $33

This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

People Also Watch

People Also Watch

PRO
Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target

PRO
Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40

PRO
Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35

PRO
BMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37

PRO
JP Morgan Maintains Overweight on Aktis Oncology, Raises Price Target to $33